Patient characteristics
| Pt. ID . | Sex . | Age . | Stage . | Year of diagnosis . | Treatment since diagnosis . | Treatment at inclusion* . |
|---|---|---|---|---|---|---|
| 1 | F | 61 | IIIA | 2006 | IFN-α, TSEBT, acitretin, bexarotene, MTX, ECP, vorinostat, prednisolone, NM, phototherapy, Calyx, topical corticosteroids | Topical corticosteroids (total of 4 times from day 0 to 2 mo) |
| 2 | M | 57 | SS | 2011 | IFN-α, acitretin, bexarotene, ECP, NM, topical corticosteroids | Bexarotene 75 mg, IFN-α, topical corticosteroids ×1-2 per week |
| 3 | M | 69 | IIIA | 2010 | IFN-α, MTX, phototherapy, TSEBT 10 Gy, NM, topical corticosteroids | Topical corticosteroids once a week |
| 4 | M | 65 | IIIA | 2015 | IFN-α, ECP, acitretin, NM, topical corticosteroids | Acitretin 20 mg, IFN-α 1.5 IE ×3 per week, NM ×2 per months, ECP, topical corticosteroids daily |
| 5 | M | 72 | IIB | 2012 | IFN-α, TSEBT, NM, localized radiotherapy, topical corticosteroids | NM ×2 per month, topical corticosteroids daily |
| 6 | M | 72 | IIB | 2006 | IFN-α, acitretin, MTX, TSEBT 30 Gy, NM, topical corticosteroids | Acitretin 25 mg, topical corticosteroids ×3-7 per week |
| 7 | M | 74 | IIB | 2007 | IFN-α, NM, topical corticosteroids | Topical corticosteroids × 2-3 per week |
| 8 | F | 61 | SS | 2011 | IFN-α, acitretin, MTX, ECP, NM, phototherapy, topical corticosteroids | IFN-α 3 mio IE ×3, methotrexate 10 mg, prednisolone 10 mg per day, ECP (not during AB treatment) |
| Pt. ID . | Sex . | Age . | Stage . | Year of diagnosis . | Treatment since diagnosis . | Treatment at inclusion* . |
|---|---|---|---|---|---|---|
| 1 | F | 61 | IIIA | 2006 | IFN-α, TSEBT, acitretin, bexarotene, MTX, ECP, vorinostat, prednisolone, NM, phototherapy, Calyx, topical corticosteroids | Topical corticosteroids (total of 4 times from day 0 to 2 mo) |
| 2 | M | 57 | SS | 2011 | IFN-α, acitretin, bexarotene, ECP, NM, topical corticosteroids | Bexarotene 75 mg, IFN-α, topical corticosteroids ×1-2 per week |
| 3 | M | 69 | IIIA | 2010 | IFN-α, MTX, phototherapy, TSEBT 10 Gy, NM, topical corticosteroids | Topical corticosteroids once a week |
| 4 | M | 65 | IIIA | 2015 | IFN-α, ECP, acitretin, NM, topical corticosteroids | Acitretin 20 mg, IFN-α 1.5 IE ×3 per week, NM ×2 per months, ECP, topical corticosteroids daily |
| 5 | M | 72 | IIB | 2012 | IFN-α, TSEBT, NM, localized radiotherapy, topical corticosteroids | NM ×2 per month, topical corticosteroids daily |
| 6 | M | 72 | IIB | 2006 | IFN-α, acitretin, MTX, TSEBT 30 Gy, NM, topical corticosteroids | Acitretin 25 mg, topical corticosteroids ×3-7 per week |
| 7 | M | 74 | IIB | 2007 | IFN-α, NM, topical corticosteroids | Topical corticosteroids × 2-3 per week |
| 8 | F | 61 | SS | 2011 | IFN-α, acitretin, MTX, ECP, NM, phototherapy, topical corticosteroids | IFN-α 3 mio IE ×3, methotrexate 10 mg, prednisolone 10 mg per day, ECP (not during AB treatment) |
ECP, extracorporal photopheresis; F, female; IFN-α, interferon alpha; M, male; mio IE, million international units; MTX, methotrexate; NM, nitrogen mustard; Pt., patient; TSEBT, total skin electron beam therapy.
CTCL-directed anticancer therapy and dosing were initiated at least 2 mo before inclusion and not changed during the study. No additional anticancer therapy was initiated throughout the study.